COMBINATION THERAPY WITH ROSUVASTATIN AND EZETIMIBE (TREZETE) IN VERY HIGH CARDIOVASCULAR RISK DYSLIPIDEMIA: EVIDENCE OF EFFICACY AND CLINICAL IMPACT

Authors

  • Fabricio Malnique
  • Guilherme Dias Queiroz
  • Deir Grassi Ribeiro da Silva
  • Carlos Rogélio de Castro Júnior
  • Vitor Verona Ceni
  • Anna Claudia Mascari
  • Diegomaier Nunes Neri
  • Rafaela da Cunha Artigas
  • Ytalo Fransoar de Brito Rego
  • Lucas Monteiro Leite
  • João Vitor Barbosa de Almeida
  • Bruna Teiga Rodrigues
  • Geovani Melanski Wassonsniki
  • Larissa Bárbara Borges Santos
  • Giovana Rocha Franzosi
  • Marina Almeida Gomes Costa
  • Adriana Lopes Machado Costa
  • Marco Aurelio Cleto Pavan
  • David Ruan Pires
  • Luis Henrique Aragão Pascoal Carneiro
  • Lucas Emericiano de Morais
  • Gabriel Rocha Naylor Dore

Keywords:

Dyslipidemia, Rosuvastatin, Ezetimibe, Combination Therapy, Cardiovascular Risk

Abstract

Very high cardiovascular risk dyslipidemia requires effective and safe strategies for intensive LDL-C reduction. This integrative review analyzed studies published between 2015 and 2025 on the combination of rosuvastatin and ezetimibe in high cardiovascular risk contexts. The literature search was conducted in PubMed, Scopus, Web of Science, SciELO, LILACS, and ScienceDirect databases. The combination demonstrated an additional LDL-C reduction of up to 25% compared to monotherapy, with a favorable safety profile and improved adherence, especially in fixed-dose formulations. Consistent results were observed in subgroups such as diabetic patients, the elderly, and those with coronary artery disease. The main limitations included short follow-up periods and a lack of comparative studies with newer lipid-lowering therapies. It is concluded that the rosuvastatin/ezetimibe combination is an effective, safe, and applicable therapeutic alternative for very high-risk populations and should be considered a first-line option in intensive cardiovascular prevention settings.

DOI: https://doi.org/10.56238/sevened2025.037-021

Downloads

Published

2025-11-10

Issue

Contemporary Dialogues in Health Sciences - 2° Edição

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Malnique, F., Queiroz, G. D., da Silva, D. G. R., de Castro Júnior, C. R., Ceni, V. V., Mascari, A. C., Neri, D. N., Artigas, R. da C., Rego, Y. F. de B., Leite, L. M., de Almeida, J. V. B., Rodrigues, B. T., Wassonsniki, G. M., Santos, L. B. B., Franzosi, G. R., Costa, M. A. G., Costa, A. L. M., Pavan, M. A. C., Pires, D. R., … Dore, G. R. N. (2025). COMBINATION THERAPY WITH ROSUVASTATIN AND EZETIMIBE (TREZETE) IN VERY HIGH CARDIOVASCULAR RISK DYSLIPIDEMIA: EVIDENCE OF EFFICACY AND CLINICAL IMPACT. Seven Editora, 316-330. https://sevenpubl.com.br/editora/article/view/8436